Allelic dosage of RB1 drives CDK4/6 inhibitor treatment resistance in metastatic breast cancer.

被引：0
|
作者：
Safonov, Anton Mikhailovich
Bandlamudi, Chaitanya
Selenica, Pier
Marra, Antonio
Ferraro, Emanuela
Mandelker, Diana
Solit, David B.
Berger, Michael F.
Norton, Larry
Powell, Simon N.
Shen, Ronglai
Robson, Mark E.
Chandarlapaty, Sarat
Reis-Filho, Jorge S.
Razavi, Pedram
机构：
[1] Hosp Univ Penn, Philadelphia, PA USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY USA
[3] Mem Sloan Kettering Canc Ctr, Milan, Italy
[4] Sloan Kettering Inst, Weill Cornell Med Coll, Kravis Ctr Mol Oncol, Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1010
引用
收藏
页数：1
相关论文
共 50 条
  • [1] RB1 SUPPRESSION IS RESPONSIBLE FOR ACQUIRED CDK4/6 INHIBITOR RESISTANCE IN GLIOBLASTOMA
    James, C. David
    Lu, Yu-Jen
    Ozawa, Tomoko
    Prados, Michael D.
    Waldman, Todd
    NEURO-ONCOLOGY, 2014, 16
  • [2] Cdk4/6 inhibitor activity in metastatic bladder cancer cell lines is independently of RB1 status
    Castellano, D.
    Rubio, C.
    Lopez-Calderon, F.
    Segovia, C.
    Duenas, M.
    Martinez-Fernandez, M.
    Otero, I.
    Manneh, R.
    De Velasco, G.
    Paramio, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer
    Martin, Miguel
    Garcia-Saenz, Jose A.
    Manso, Luis
    Llombart, Antonio
    Cassinello, Alejo
    Atienza, Manuel
    Ringeisen, Francois
    Ciruelos, Eva
    FUTURE ONCOLOGY, 2020, 16 (33) : 2763 - 2778
  • [4] Chemotherapy modulates CDK4/6 inhibitors resistance in metastatic breast cancer by Rb1 mutations: a case report and literature review
    Gao, Lu
    Shen, Xiabo
    He, Libin
    Wu, Jiayi
    Liu, Yiyuan
    Wang, Xiaojia
    Shao, Xiying
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (02)
  • [5] Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer
    Condorelli, R.
    Spring, L.
    O'Shaughnessy, J.
    Lacroix, L.
    Bailleux, C.
    Scott, V.
    Dubois, J.
    Nagy, R. J.
    Lanman, R. B.
    Iafrate, A. J.
    Andre, F.
    Bardia, A.
    ANNALS OF ONCOLOGY, 2018, 29 (03) : 640 - 645
  • [6] Treatment with CDK4/6 Inhibitor in a Patient with Metastatic Breast Cancer Causing Myelophthisis
    Dahake, Nikita
    Senchak, Jordan
    Nasibli, Jalil
    Incorvati, Jason
    CANCER RESEARCH, 2024, 84 (09)
  • [7] CDK4/6 Inhibitors in the Treatment of Metastatic Breast Cancer
    Ettl, Johannes
    Huober, Jens
    Lueftner, Diana
    Marme, Frederik
    Wuerstlein, Rachel
    BREAST CARE, 2017, 12 (02) : 118 - 120
  • [8] High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
    Marta Palafox
    Laia Monserrat
    Meritxell Bellet
    Guillermo Villacampa
    Abel Gonzalez-Perez
    Mafalda Oliveira
    Fara Brasó-Maristany
    Nusaibah Ibrahimi
    Srinivasaraghavan Kannan
    Leonardo Mina
    Maria Teresa Herrera-Abreu
    Andreu Òdena
    Mònica Sánchez-Guixé
    Marta Capelán
    Analía Azaro
    Alejandra Bruna
    Olga Rodríguez
    Marta Guzmán
    Judit Grueso
    Cristina Viaplana
    Javier Hernández
    Faye Su
    Kui Lin
    Robert B. Clarke
    Carlos Caldas
    Joaquín Arribas
    Stefan Michiels
    Alicia García-Sanz
    Nicholas C. Turner
    Aleix Prat
    Paolo Nuciforo
    Rodrigo Dienstmann
    Chandra S. Verma
    Nuria Lopez-Bigas
    Maurizio Scaltriti
    Monica Arnedos
    Cristina Saura
    Violeta Serra
    Nature Communications, 13
  • [9] Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
    Li, Zhen
    Zou, Wei
    Zhang, Ji
    Zhang, Yunjiao
    Xu, Qi
    Li, Siyuan
    Chen, Ceshi
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [10] CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
    Rubio, Carolina
    Martinez-Fernandez, Monica
    Segovia, Cristina
    Lodewijk, Iris
    Suarez-Cabrera, Cristian
    Segrelles, Carmen
    Lopez-Calderon, Fernando
    Munera-Maravilla, Ester
    Santos, Mirentxu
    Bernardini, Alejandra
    Garcia-Escudero, Ramon
    Lorz, Corina
    Jose Gomez-Rodriguez, Maria
    de Velasco, Guillermo
    Otero, Irene
    Villacampa, Felipe
    Guerrero-Ramos, Felix
    Ruiz, Sergio
    de la Rosa, Federico
    Dominguez-Rodriguez, Sara
    Real, Francisco X.
    Malats, Nuria
    Castellano, Daniel
    Duenas, Marta
    Paramio, Jesus M.
    CLINICAL CANCER RESEARCH, 2019, 25 (01) : 390 - 402
12345